Will mixed chimerism cure autoimmune diseases after a nonmyeloablative stem cell transplant?

Suparno Chakrabarti, SK Handa, RJ Bryon, Michael Griffiths, Donald Milligan

Research output: Contribution to journalArticle

31 Citations (Scopus)


BACKGROUND Mixed chimerism after allogeneic bone marrow transplantation has been shown to cure a number of genetic disorders in both the clinical and experimental settings. Although encouraging results have been reported from animal experiments, the role of mixed chimerism in eliminating autoimmune disorders is not clear. METHODS A 50-year-old man with extensive psoriasis received an allogeneic transplant from his brother after nonmyeloablative conditioning with fludarabine, melphalan, and Campath-1H for relapsed non-Hodgkin's lymphoma. The chimerism status and the immunological recovery after the transplant were serially monitored. RESULTS Twenty-one months after the transplant, the patient continues to be in complete remission from psoriasis and lymphoma with stable mixed chimerism (30% to 40% donor cells), despite significant recovery of T-cell subsets and antigen-specific response. CONCLUSIONS If mixed chimerism can be achieved safely with novel low-intensity conditioning regimens and results in sustained remission of autoimmune diseases, allogeneic transplantation may become a realistic therapy in the management of some patients with autoimmune disease.
Original languageEnglish
Pages (from-to)340-2
Number of pages3
Issue number2
Publication statusPublished - 27 Jul 2001


Dive into the research topics of 'Will mixed chimerism cure autoimmune diseases after a nonmyeloablative stem cell transplant?'. Together they form a unique fingerprint.

Cite this